← Back to Clinical Trials
Recruiting NCT07273526

NCT07273526 Adrenaline V/s Dopamine in Fuid Refractory Septic Shock

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07273526
Status Recruiting
Phase
Sponsor Laiba Qamar
Condition Fluid Refractory Septic Shock
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2025-06-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 1 Month
Max Age 12 Months
Study Type INTERVENTIONAL
Interventions
AdrenalineDopamine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2025-06-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study compares the efficacy of two drugs i.e Adrenaline and dopamine in fluid refractory type of septic shock which is a dreadful medical condition especially in children. The efficacy will be checked based on heart rate , GCS, capillary refill time , palpable pripheral pulse , urine output and systolic blood pressure.

Eligibility Criteria

Inclusion Criteria: Patients of both Genders having age range between 1month and 12 years with diagnosis of fluid refractory septic shock as per operational definition. \- Exclusion Criteria: * Patients with 1. cardiopumonary Bypass during last 5 days 2. Chronic Systemic disease like Chronic kidney Disease , cerebral palsy, congenital heart disease 3. neuromuscular discorder 4. Metabolic disorders 5. Those who already had treatment at periphery for hypovolemia without any record of medication or sequential organ failure at presentation

Contact & Investigator

Central Contact

Hafiz Muhammad Abdullah Dr, MBBS

✉ mbilal1857@gmail.com

📞 03440846288

Frequently Asked Questions

Who can join the NCT07273526 clinical trial?

This trial is open to participants of all sexes, aged 1 Month or older, up to 12 Months, studying Fluid Refractory Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07273526 currently recruiting?

Yes, NCT07273526 is actively recruiting participants. Contact the research team at mbilal1857@gmail.com for enrollment information.

Where is the NCT07273526 trial being conducted?

This trial is being conducted at Faisalābad, Pakistan.

Who is sponsoring the NCT07273526 clinical trial?

NCT07273526 is sponsored by Laiba Qamar. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology